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Th   e two breast cancer genes BRCA1 and BRCA2 account 
for approximately one-half of cases of hereditary breast 
cancer, and other genes, such as BRIP1, PALB2, and P53, 
account for a small additional fraction [1]. Recently, it has 
been proposed that RAD51C is also a breast cancer 
suscep  tibility gene [2]. A bi-allelic mutation of RAD51C
was originally found in a family from Pakistan with 
features of Fanconi anemia [3]. Because several genes in 
the Fanconi anemia gene family are also breast cancer 
susceptibility genes (including BRCA2 ( FANCD1) [4], 
BRIP1 (FANCJ) [5] and PALB2 (FANCN) [6]), Meindl and 
colleagues hypothesised that RAD51C might be a breast 
cancer gene [2]. A germline mutation was seen in 6 of 
480 (1.3%) breast/ovarian cancer families from Germany, 
which had previously been found to be negative for muta-
tions in BRCA1 and BRCA2. In each of the six families, 
the putative mutation co-segregated with the relevant 
cancers [2]. Each family with a mutation contained at 
least one case each of breast and ovarian cancer.
In order to conﬁ  rm these ﬁ  ndings, we sequenced the 
nine coding exons of RAD51C in the germline DNA of 
454 patients with familial breast/ovarian cancer. Th  e 
mean age at diagnosis of the breast cancers was 44.7 
years (range 21 to 65) and the mean age of diagnosis of 
the ovarian cancers was 47.9 years (range 23 to 60 years). 
All patients were previously found to be negative for 
BRCA1 and BRCA2 mutations. Each proband had at least 
two aﬀ  ected ﬁ  rst- or second-degree relatives. Eighty-ﬁ  ve 
percent of the families contained at least one case of 
ovarian cancer. One-hundred patients were Jewish, 152 
were French-Canadian and 202 were of various other 
ethnic origins. All subjects provided written informed 
consent to participate in the study. Th  e study protocol 
was approved by the ethics committee of the Women’s 
College Research Institute, protocol number 
2007-0036-B.
We found no deleterious RAD51C mutation among the 
454 patients. We found a novel c.146-8A>G  splicing 
variant in three of 100 Jewish breast cancer patients, but 
this variant was also present in 12 of 190 Jewish controls. 
In addition, we found one polymorphic missense variant 
(p.126Ala>Th   r or rs61758784) in three patients and one 
(p.287Th   r>Ala or rs28363317) in four patients. Based on 
the prevalence of mutations in the initial report [2], we 
expected to identify approximately ﬁ  ve families with a 
deleterious germline RAD51C mutation. It is of interest 
that the mutations in the German families were all 
diﬀ  erent, and therefore the discrepant results cannot be 
explained by the presence of RAD51C founder alleles in 
Germany. Perhaps RAD51C mutations are not as 
common as the initial report suggests.
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